Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of October 2018, specifically dated October 11, 2018. The filing announces a strategic Master Clinical Trial Collaboration Agreement with Bristol-Myers Squibb Company (BMS) to evaluate Compugen's investigational anti-PVRIG antibody, COM701, in combination with BMS's Opdivo (nivolumab) for advanced solid tumors.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements such as revenue, profit, cash flow, or operating margins. The primary financial event disclosed is a capital transaction:
- Equity Investment: BMS is making a $12 million equity investment in Compugen.
- Share Purchase: BMS will purchase 2,424,243 ordinary shares of Compugen.
- Purchase Price: $4.95 per share.
- Premium: The price represents a 33% premium over the average closing price of Compugen's shares for the 20 trading days prior to execution.
- Closing Date: Expected on or about October 12, 2018, subject to customary conditions.
Material Changes and Collaboration Terms
The material change is the entry into the collaboration agreement, which alters Compugen's development strategy and capital structure. Key terms include:
- Clinical Scope: Compugen will sponsor a two-part Phase 1 trial evaluating the combination in four tumor types: non-small cell lung, ovarian, breast, and endometrial cancer. BMS will supply Opdivo at no cost for the combination arm.
- Future Studies: The agreement addresses potential future combinations, including trials sponsored by BMS to investigate combined inhibition of PVRIG and TIGIT.
- Cost Allocation: Each party is responsible for costs associated with the study it conducts.
- Intellectual Property: Compugen retains ownership and global commercial rights to COM701. Both parties grant each other non-exclusive, royalty-free licenses under certain patents to seek regulatory approval and market the compounds solely for use in the combined therapy.
- Exclusivity and Negotiation: Compugen must negotiate with BMS for an exclusive license before licensing COM701 to others during a defined "Exclusivity Period" (ending 6 to 12 months after the Compugen-sponsored study completion). If no agreement is reached within a three-month "Negotiation Period," Compugen is free to license to others.
Outlook, Risks, and Management Commentary
Management views this collaboration as a validation of the biological rationale for the PVRIG pathway and the synergistic activity demonstrated in preclinical models. The agreement allows Compugen to advance its lead asset with a major pharmaceutical partner while retaining commercial rights.
Risks and Contingencies:
- The agreement is subject to termination for breach, bankruptcy, material safety issues, or clinical hold.
- The equity investment is subject to customary closing conditions.
- Compugen is restricted from conducting research or granting rights to certain third parties regarding the combination of anti-PD-1/PD-L1 antagonists with COM701 during the Exclusivity Period, though it remains free to collaborate with academic or non-profit entities.
Investor Verification Checklist
- Verify the closing of the $12 million equity investment and the issuance of 2,424,243 shares.
- Confirm the initiation and enrollment status of the Phase 1 trial for COM701 in combination with Opdivo.
- Monitor the "Exclusivity Period" timeline to understand when Compugen may freely license COM701 to other parties.
- Review the specific terms of the royalty-free licenses granted to BMS to ensure they do not impede future commercialization outside the combination therapy scope.
- Track any updates regarding the potential BMS-sponsored studies investigating PVRIG and TIGIT combinations.